🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

RecruitingEARLY Phase 1Ages 18 Years - anyAllRayzeBio, Inc.
NCT07671092 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Are at least 18 years old at the time of signing the informed consent form (ICF) * Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC Exclusion Criteria: * For Women of Childbearing Potential: Are pregnant or breastfeeding Note: Additional criteria may apply and will be assessed by the study site
💊

What it tests

  • RYZ211/212
📍

Where

6 sites
Research Facility
St Leonards, Australia
Research Facility
Nedlands, Australia
Research Facility
Perth, Australia
Research Facility
Christchurch, New Zealand
Research Facility
Johannesburg, South Africa
Research Facility
Pretoria, South Africa
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy